Company Insights

BIAF customer relationships

Explore interactive graphBrowse insights index
BIAF customer relationship map

What bioAffinity’s customer footprint tells investors about commercialization risk and upside

bioAffinity Technologies (BIAF) develops and commercializes CyPath™ Lung, a non‑invasive diagnostic test, and monetizes through a mix of direct patient laboratory services, a corporate lab subsidiary offering an LDT go‑to‑market pathway, and selective institutional research sales. Revenue today is driven by fee‑for‑service lab receipts and limited government R&D purchases, while the strategic path to scale layers CE/FDA regulatory milestones and geographic rollout. For investors assessing BIAF’s customer relationships, the pattern is clear: early commercialization via laboratory services and hospital/physician channels, supplemented by one‑off institutional studies, not yet a recurring payer‑reimbursed model. Learn more and explore the full relationship map at https://nullexposure.com/.

How BIAF actually sells CyPath Lung — a concise thesis for investors

bioAffinity operates a two‑track commercialization model: a laboratory services arm (Precision Pathology Laboratory Services, PPLS, and Village Oaks operations) that bills patients and third‑party payors for CyPath‑related testing today, and targeted institutional customers (including government research buyers) for observational and development studies. Monetization is primarily transaction‑based lab fees augmented by strategic proprietary positioning as an LDT to accelerate market access before broad regulatory approval. For investors, the current business is high‑margin per‑test when volume exists but limited by market penetration, reimbursement, and concentration risk. If you want a structured view of customer exposure, visit https://nullexposure.com/ for our relationship breakdown and signal map.

The customer relationships you need to know

This section documents every customer relationship disclosed in company filings and public reporting. Each relationship is summarized in plain English with the source noted.

  • U.S. Department of Defense: bioAffinity sold CyPath Lung tests to the U.S. Department of Defense for an observational study, including research into bronchoalveolar lavage fluid for cardiopulmonary assessment post‑COVID; this is an institutional, research‑oriented buyer rather than routine clinical reimbursement. According to the company’s 10‑K (FY2024), CyPath Lung tests were purchased by the DOD for an observational study and related R&D (FY2024 10‑K).
    Key takeaway: Government purchases are project‑specific and research‑focused rather than an indicator of broad commercial reimbursement.

  • Village Oaks: Village Oaks receives clinical flow cytometry services from bioAffinity related to the CyPath Lung test, indicating an internal laboratory services relationship and operational integration in testing workflows. The FY2024 10‑K discloses clinical flow cytometry services provided to Village Oaks in support of CyPath Lung (FY2024 10‑K).
    Key takeaway: Village Oaks represents an operational lab node—these are service arrangements that reflect the company’s reliance on in‑house and affiliate lab capacity.

  • Precision Pathology Laboratory Services (PPLS): CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, which positions PPLS as the commercial channel for physician and patient orders. A news report referenced the LDT positioning and patent acceptance context (news coverage, 2026 reporting on FY2025 developments).
    Key takeaway: PPLS is the company’s commercial shopfront for the LDT strategy, critical for early revenue capture and physician adoption ahead of regulatory milestones.

What the relationship map reveals about operating constraints and model characteristics

The disclosed relationships and company commentary generate several company‑level signals that drive investment thesis and risk assessment:

  • Contracting posture — transactional and projectized. Most revenue is fee‑for‑service to patients (transactional) and discrete contracts for research (projectized), including the DOD observational study. This implies revenue volatility tied to test volume and episodic institutional studies.

  • Customer concentration and criticality. The customer base is fragmented by nature (patients and physicians) but concentrated in strategic channels—PPLS and Village Oaks control the delivery path; a single large institutional buyer like the DOD is project‑critical but not a durable revenue stream. Concentration of lab operations within affiliated entities increases operational leverage but also single‑point risks.

  • Maturity and commercial staging. The company is in early commercialization: Phase 1 LDT launch completed in Texas and plans for staged EMEA entry (Netherlands first) and broader global expansion post‑FDA. These signals indicate a phased, regulated path to scale rather than mature, reimbursed national billing. Evidence of planned geographic rollouts and FDA strategy is embedded in corporate filings (company business plan statements, FY2024 filing).

  • Counterparty mix and payor dynamics. Company commentary confirms three counterparty types: government institutions (e.g., DOD), individual patients (fee‑paying or physician‑requested services), and third‑party payors (insurers, government payors) who ultimately adjudicate payment. Reimbursement uncertainty and third‑party contracting posture represent the primary bottlenecks to volume growth.

  • Segment focus — services first. Management defines two reporting segments: diagnostic R&D and laboratory services, with laboratory services encompassing Village Oaks and PPLS operations plus CyPath sales and marketing costs. This confirms that current economics are driven by lab services rather than a pure product royalty model.

Financial and commercial implications for investors

The customer evidence and company signals translate into concrete investment risks and potential upside:

  • Risk: Revenue volatility and limited payer coverage. Given the fee‑for‑service model and early LDT positioning, revenue depends on organic physician adoption, localized lab capacity, and episodic institutional contracts rather than durable payer contracts. Current trailing revenue is modest relative to R&D and operating losses (company filings show negative EBITDA and net losses through 2025).

  • Opportunity: Regulatory and geographic inflection points. Successful CE marking, staged EU expansion, and eventual FDA authorization would materially reframe go‑to‑market economics by unlocking broader markets and payer negotiations. PPLS and Village Oaks provide immediate distribution capability to exploit such inflection points.

  • Operational leverage via affiliated labs. Owning PPLS and working with Village Oaks concentrates operations, reducing third‑party dependency for test delivery and data capture—this is a strategic strength that accelerates iteration and margin capture if volume scales.

If you want a systematic breakdown of contractual counterparties, concentration scores, and exposure timelines, visit https://nullexposure.com/ for the structured relationship analysis and source maps.

Investor takeaway and recommended next steps

bioAffinity’s customer footprint is consistent with an early‑stage diagnostics company monetizing through controlled lab services and targeted institutional research purchases. The path to materially larger and predictable revenues runs through regulatory approvals and payer contracting; until then, revenues will reflect lab throughput, research contracts, and local adoption. For investors focused on commercialization risk versus regulatory upside, the most relevant signals are PPLS’s role as the LDT seller, Village Oaks’ operational role, and the presence of research buyers such as the DOD.

Explore the full evidence base and relationship network at https://nullexposure.com/ to quantify counterparty concentration and track the regulatory milestones that will determine valuation.